Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Real-world disease progression in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
Authors:
Hanna K. Gaggin1; Weilong Li2; Monika Semwal2; Ashley Goss2; Myriam Asmar2; Chioma Uzoigwe2; Yan Wang3; Ariel Chao3; Kat Wolf Khachatourian2; Yan Song4